Decreased cardiovascular mortality in the ITALUNG lung cancer screening trial: Analysis of underlying factors.
Aged
Case-Control Studies
Coronary Artery Disease
/ etiology
Databases, Factual
Early Detection of Cancer
/ statistics & numerical data
Female
Follow-Up Studies
Humans
Lung Neoplasms
/ complications
Male
Middle Aged
Randomized Controlled Trials as Topic
Retrospective Studies
Risk Factors
Survival Rate
Tomography, X-Ray Computed
/ methods
Vascular Calcification
/ etiology
Cardiovascular mortality
Coronary arteries calcifications
Lung cancer screening
Journal
Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
28
06
2019
revised:
02
10
2019
accepted:
07
10
2019
pubmed:
28
10
2019
medline:
2
9
2020
entrez:
27
10
2019
Statut:
ppublish
Résumé
In the ITALUNG lung cancer screening trial after 9.3 years of follow-up we observed an unexpected significant decrease of cardiovascular (CV) mortality in subjects invited for low-dose CT (LDCT) screening as compared to controls undergoing usual care. Herein we extended the mortality follow-up and analyzed the potential factors underlying such a decrease. The following factors were assessed in screenes and controls: burden of CV disease at baseline, changes in smoking habits, use of CV drugs and frequency of planned vascular procedures after randomisation. Moreover, in the screenes we evaluated inclusion of presence of coronary artery calcification (CAC) in the LDCT report form that was transmitted to the participant and his/her General Practitioner. The 2-years extension of follow-up confirmed a significant decrease of CV mortality in the subjects of the active group compared to control subjects (15.6 vs 34.0 per 10,000; p = 0.001) that was not observed in the drops-out of the active group. None of the explaining factors we considered significantly differed between active and control group. However, the subjects of the active group with reported CAC experienced a not significantly lower CV mortality and showed a significantly higher use of CV drugs and frequency of planned vascular procedures than the control group. LDCT screening for lung cancer offers the opportunity for detection of CAC that is an important CV risk factor. Although the underlying mechanisms are not clear, our results suggest that the inclusion of information about CAC presence in the LDCT report may represent a candidate factor to explain the decreased CV mortality observed in screened subjects of the ITALUNG trial, possibly resulting in intervention for patient care to prevent CV deaths. Further studies investigating whether prospective reporting and rating of CAC have independent impact on such interventions and CV mortality are worthy.
Identifiants
pubmed: 31654837
pii: S0169-5002(19)30676-2
doi: 10.1016/j.lungcan.2019.10.006
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT02777996']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
72-78Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.